VivoSeq
Other

Phase 1

0

Pipeline Programs↗

82

Active Trials↗

186

Companies Involved↗

Phase 1 is an early-stage landscape with 0 programs across 186 companies. The most active players are Pfizer, Vertex Pharmaceuticals, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

65/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

495

clinical trials

Completed354 · 72%
Recruiting37 · 7%
Terminated25 · 5%
Not yet recruiting23 · 5%
Unknown status20 · 4%
Active, not recruiting20 · 4%
Other16 · 3%

Clinical Trials

Trial Activity

495 trials

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Recruiting·11Globe Health Institute·Phase 1·NCT06694935·52 enrolled
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
Recruiting·SSagimet Biosciences Inc.·Phase 1·NCT06989840·128 enrolled
Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants
Recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT07457229·40 enrolled
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Recruiting·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 1·NCT07230652·40 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Recruiting·IIambic Therapeutics, Inc·Phase 1·NCT06253871·243 enrolled
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Recruiting·AAbCellera Biologics Inc.·Phase 1·NCT07108894·40 enrolled
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers
Recruiting·BBugworks Research Inc.·Phase 1·NCT07029932·48 enrolled
A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects
Recruiting·TTIXiMED, Inc.·Phase 1·NCT06800729·35 enrolled
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
Recruiting·AAptabio Therapeutics, Inc.·Phase 1·NCT07330674·68 enrolled
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06977880·80 enrolled
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Recruiting·Roche logoRoche·Phase 1·NCT06371417·144 enrolled
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
Recruiting·AbbVie logoAbbVie·Phase 1·NCT07306754·66 enrolled
Phase 1 Study of PRX019 in Healthy Adult Volunteers
Recruiting·PProthena Biosciences Ltd.·Phase 1·NCT06699680·48 enrolled
The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects
Recruiting·AAspargo Labs, Inc·Phase 1·NCT06872866·12 enrolled
A Phase 1 Study of GS101 Injection
Recruiting·JJiangsu Genscend Biopharmaceutical Co., Ltd·Phase 1·NCT07411755·294 enrolled
Page 1 of 33

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)